Coastal Investment Advisors Inc. decreased its position in Teladoc Health, Inc. (NYSE:TDOC – Get Rating) by 18.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,836 shares of the health services provider’s stock after selling 648 shares during the quarter. Coastal Investment Advisors Inc.’s holdings in Teladoc Health were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in the stock. Traynor Capital Management Inc. acquired a new position in Teladoc Health in the 1st quarter valued at about $222,000. Autus Asset Management LLC acquired a new position in Teladoc Health in the 1st quarter valued at about $639,000. Veriti Management LLC acquired a new position in shares of Teladoc Health during the 1st quarter valued at about $264,000. Sanders Morris Harris LLC increased its stake in shares of Teladoc Health by 44.6% during the 1st quarter. Sanders Morris Harris LLC now owns 12,315 shares of the health services provider’s stock valued at $888,000 after acquiring an additional 3,800 shares during the last quarter. Finally, SOA Wealth Advisors LLC. increased its stake in shares of Teladoc Health by 455.5% during the 1st quarter. SOA Wealth Advisors LLC. now owns 611 shares of the health services provider’s stock valued at $44,000 after acquiring an additional 501 shares during the last quarter. 87.17% of the stock is owned by hedge funds and other institutional investors.
In other news, SVP Daniel Trencher sold 1,000 shares of the stock in a transaction that occurred on Friday, June 17th. The stock was sold at an average price of $29.12, for a total transaction of $29,120.00. Following the completion of the transaction, the senior vice president now directly owns 28,408 shares in the company, valued at approximately $827,240.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.55% of the company’s stock.
A number of research firms have recently commented on TDOC. Argus downgraded shares of Teladoc Health from a “buy” rating to a “hold” rating in a research note on Thursday, May 5th. Canaccord Genuity Group dropped their price objective on shares of Teladoc Health from $112.00 to $50.00 in a research note on Thursday, April 28th. Wells Fargo & Company downgraded shares of Teladoc Health from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $104.00 to $40.00 in a research note on Thursday, April 28th. Citigroup downgraded shares of Teladoc Health from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $115.00 to $43.00 in a research note on Thursday, April 28th. Finally, The Goldman Sachs Group dropped their price objective on shares of Teladoc Health from $77.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, May 26th. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $88.36.
Teladoc Health stock opened at $37.17 on Friday. The stock has a market cap of $5.99 billion, a P/E ratio of -0.86 and a beta of 0.81. The company has a current ratio of 3.94, a quick ratio of 3.71 and a debt-to-equity ratio of 0.17. The stock has a 50 day moving average of $37.40 and a 200-day moving average of $62.20. Teladoc Health, Inc. has a 52 week low of $27.38 and a 52 week high of $174.32.
Teladoc Health (NYSE:TDOC – Get Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.08. The company had revenue of $565.35 million during the quarter, compared to analysts’ expectations of $568.91 million. Teladoc Health had a negative return on equity of 2.12% and a negative net margin of 321.94%. During the same period in the prior year, the business posted $0.13 EPS. As a group, equities analysts predict that Teladoc Health, Inc. will post -2.05 earnings per share for the current fiscal year.
Teladoc Health Company Profile (Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
Featured Stories
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC – Get Rating).
Receive News & Ratings for Teladoc Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teladoc Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
